MDT 在食管胃结合部腺癌治疗中的作用_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 田艳涛 , 马福海

国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院胰胃外科（北京 100021）;

Corresponding author：

田艳涛, Email: tyt67@163.com

Keywords：

DOI：

10.7507/1007-9424.201907001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 田艳涛, 马福海. MDT 在食管胃结合部腺癌治疗中的作用. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(9): 1035-1039. doi: 10.7507/1007-9424.201907001 Copy

1.	Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol, 2013, 23(1): 3-9.
2.	Nagami Y, Ominami M, Otani K, et al. Endoscopic submucosal dissection for adenocarcinomas of the esophagogastric junction. Digestion, 2018, 97(1): 38-44.
3.	Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 2012, 143(2): 336-346.
4.	Hatta W, Tong D, Lee YY, et al. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc, 2017, 29 Suppl 2: 18-25.
5.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
6.	Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: A single-institution, high-volume experience in China. Ann Surg, 2016, 263(1): 88-95.
7.	Hosoda K, Yamashita K, Katada N, et al. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg, 2015, 63(10): 549-556.
8.	Al-Batran SE, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin North Am, 2017, 31(3): 441-452.
9.	国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018 年版). 中华胃肠外科杂志, 2018, 21(9): 961-975.
10.	Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014(ver. 4). Gastric Cancer, 2017, 20(1): 1-19.
11.	Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg, 1998, 85(11): 1457-1459.
12.	Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol, 2012, 19(2): 677-683.
13.	Lehmann K, Schneider PM. Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res, 2010, 182: 65-72.
14.	van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomichybridization of cancer of the gastroesophageal junction: deletionof 14Q31-32.1 discriminates between esophageal (Barrett’s) and gastric cardia adenocarcinomas. Cancer Res, 1999, 59(3): 748-752.
15.	Curtis NJ, Noble F, Bailey IS, et al. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol, 2014, 109(3): 202-207.
16.	Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1. 2015. J Natl Compr Canc Netw, 2015, 13(2): 194-227.
17.	万丽娟, 张红梅. 食管胃结合部腺癌的影像诊断与分型特征. 中国医学前沿杂志(电子版), 2017, 9(5): 6-10.
18.	Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1 602 consecutive resected patients. Surg Oncol Clin N Am, 2006, 15(4): 751-764.
19.	Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery, 2015, 157(3): 551-555.
20.	Yoshikawa T, Takeuchi H, Hasegawa S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer, 2016, 19(1): 143-149.
21.	Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer, 2017, 20(Suppl 1): 69-83.
22.	日本胃癌學會. 胃癌治療ガイドライン. 5 版. 東京: 金原出版株式会社, 2018.
23.	Mine S, Kurokawa Y, Takeuchi H, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type Ⅱ tumors. Eur J Surg Oncol, 2015, 41(10): 1348-1353.
24.	Hashimoto T, Kurokawa Y, Mori M, et al. Surgical treatment of gastroesophageal junction cancer. J Gastric Cancer, 2018, 18(3): 209-217.
25.	Cense HA, Sloof GW, Klaase JM, et al. Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. J Nucl Med, 2004, 45(2): 247-252.
26.	de Manzoni G, Pedrazzani C, Di Leo A, et al. Metastases to the para-aortic lymph nodes in adenocarcinoma of the cardia. Eur J Surg, 2001, 167(6): 413-418.
27.	Hasegawa S, Yoshikawa T, Rino Y, et al. Priority of lymph node dissection for Siewert type Ⅱ/Ⅲ adenocarcinoma of the esophagogastric junction. Ann Surg Oncol, 2013, 20(13): 4252-4259.
28.	Mine S, Sano T, Hiki N, et al. Lymphadenectomy around the left renal vein in Siewert type Ⅱ adenocarcinoma of the oesopha-gogastric junction. Br J Surg, 2013, 100(2): 261-266.
29.	Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med, 2002, 347(21): 1662-1669.
30.	Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg, 2007, 246(6): 992-1000.
31.	Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol, 2006, 7(8): 644-651.
32.	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
33.	Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
34.	Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev, 2013, (5): CD008107.
35.	Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol, 2016, 17(12): 1697-1708.
36.	Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 2008, 26(7): 1086-1092.
37.	van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
38.	Petrelli F, Ghidini M, Barni S, et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Gastric Cancer, 2019, 22(2): 245-254.
39.	Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase Ⅲ trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16: 503.
40.	Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 2007, 357(18): 1810-1820.
41.	Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol, 2011, 29(33): 4387-4393.
42.	Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(12): 1389-1396.
43.	Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345(10): 725-730.
44.	Cats A, Jansen E, van Grieken N, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5): 616-628.
45.	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
46.	Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15(11): 1224-1235.
47.	Birla R, Hoara P, Caragui A, et al. Current management of locally advanced junction esophagogastric adenocarcinoma. Chirurgia (Bucur), 2018, 113(1): 38-45.

1. Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol, 2013, 23(1): 3-9.
2. Nagami Y, Ominami M, Otani K, et al. Endoscopic submucosal dissection for adenocarcinomas of the esophagogastric junction. Digestion, 2018, 97(1): 38-44.
3. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 2012, 143(2): 336-346.
4. Hatta W, Tong D, Lee YY, et al. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc, 2017, 29 Suppl 2: 18-25.
5. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
6. Liu K, Yang K, Zhang W, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: A single-institution, high-volume experience in China. Ann Surg, 2016, 263(1): 88-95.
7. Hosoda K, Yamashita K, Katada N, et al. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg, 2015, 63(10): 549-556.
8. Al-Batran SE, Lorenzen S. Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin North Am, 2017, 31(3): 441-452.
9. 国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018 年版). 中华胃肠外科杂志, 2018, 21(9): 961-975.
10. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014(ver. 4). Gastric Cancer, 2017, 20(1): 1-19.
11. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg, 1998, 85(11): 1457-1459.
12. Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol, 2012, 19(2): 677-683.
13. Lehmann K, Schneider PM. Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res, 2010, 182: 65-72.
14. van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomichybridization of cancer of the gastroesophageal junction: deletionof 14Q31-32.1 discriminates between esophageal (Barrett’s) and gastric cardia adenocarcinomas. Cancer Res, 1999, 59(3): 748-752.
15. Curtis NJ, Noble F, Bailey IS, et al. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol, 2014, 109(3): 202-207.
16. Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1. 2015. J Natl Compr Canc Netw, 2015, 13(2): 194-227.
17. 万丽娟, 张红梅. 食管胃结合部腺癌的影像诊断与分型特征. 中国医学前沿杂志(电子版), 2017, 9(5): 6-10.
18. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1 602 consecutive resected patients. Surg Oncol Clin N Am, 2006, 15(4): 751-764.
19. Kurokawa Y, Hiki N, Yoshikawa T, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery, 2015, 157(3): 551-555.
20. Yoshikawa T, Takeuchi H, Hasegawa S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer, 2016, 19(1): 143-149.
21. Yamashita H, Seto Y, Sano T, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer, 2017, 20(Suppl 1): 69-83.
22. 日本胃癌學會. 胃癌治療ガイドライン. 5 版. 東京: 金原出版株式会社, 2018.
23. Mine S, Kurokawa Y, Takeuchi H, et al. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type Ⅱ tumors. Eur J Surg Oncol, 2015, 41(10): 1348-1353.
24. Hashimoto T, Kurokawa Y, Mori M, et al. Surgical treatment of gastroesophageal junction cancer. J Gastric Cancer, 2018, 18(3): 209-217.
25. Cense HA, Sloof GW, Klaase JM, et al. Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. J Nucl Med, 2004, 45(2): 247-252.
26. de Manzoni G, Pedrazzani C, Di Leo A, et al. Metastases to the para-aortic lymph nodes in adenocarcinoma of the cardia. Eur J Surg, 2001, 167(6): 413-418.
27. Hasegawa S, Yoshikawa T, Rino Y, et al. Priority of lymph node dissection for Siewert type Ⅱ/Ⅲ adenocarcinoma of the esophagogastric junction. Ann Surg Oncol, 2013, 20(13): 4252-4259.
28. Mine S, Sano T, Hiki N, et al. Lymphadenectomy around the left renal vein in Siewert type Ⅱ adenocarcinoma of the oesopha-gogastric junction. Br J Surg, 2013, 100(2): 261-266.
29. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med, 2002, 347(21): 1662-1669.
30. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg, 2007, 246(6): 992-1000.
31. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol, 2006, 7(8): 644-651.
32. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355(1): 11-20.
33. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial. J Clin Oncol, 2011, 29(13): 1715-1721.
34. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev, 2013, (5): CD008107.
35. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol, 2016, 17(12): 1697-1708.
36. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 2008, 26(7): 1086-1092.
37. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012, 366(22): 2074-2084.
38. Petrelli F, Ghidini M, Barni S, et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Gastric Cancer, 2019, 22(2): 245-254.
39. Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase Ⅲ trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16: 503.
40. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 2007, 357(18): 1810-1820.
41. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol, 2011, 29(33): 4387-4393.
42. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15(12): 1389-1396.
43. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345(10): 725-730.
44. Cats A, Jansen E, van Grieken N, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol, 2018, 19(5): 616-628.
45. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
46. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15(11): 1224-1235.
47. Birla R, Hoara P, Caragui A, et al. Current management of locally advanced junction esophagogastric adenocarcinoma. Chirurgia (Bucur), 2018, 113(1): 38-45.

Previous Article
腔镜食管胃结合部癌消化道重建方式的选择
Next Article
Definition, classification, and staging for adenocarcinoma of esophagogastric junction: updates in controversies

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

MDT 在食管胃结合部腺癌治疗中的作用

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content